FDA grants Kowa’s pemafibrate breakthrough therapy designation for PBC

Japan-based Kowa Company, Ltd. announced on June 30 that the US FDA granted Breakthrough Therapy Designation (BTD) to K-808 (pemafibrate), a selective peroxisome proliferator-activated receptor alpha (PPARα) modulator (SPPARMα), for the treatment of primary biliary cholangitis (PBC). The designation, received on June 11, was based on preliminary data from the ongoing Phase II clinical trial K-808-2.01, which the company reported demonstrated a statistically significant reduction in alkaline phosphatase (ALP) levels — a validated surrogate endpoint for disease progression in PBC. The designation positions Kowa’s pemafibrate BTD as the first formal US regulatory recognition for the molecule, which has been approved in Japan since 2018 under the brand name Parmodia Tablets for hyperlipidemia.

Breakthrough Therapy Designation provides intensive guidance from senior FDA staff and all the benefits of Fast Track Designation, including eligibility for rolling review. Kowa has not previously disclosed any other FDA expedited designations for pemafibrate in PBC.

Kowa is developing K-808 for two patient populations: adults with an inadequate response to ursodeoxycholic acid (UDCA), the established first-line therapy for PBC, in whom pemafibrate would be used as a combination partner; and patients unable to tolerate UDCA, for whom monotherapy is intended. The company has stated its goal is global approval, including in the US and Japan.

PBC is a chronic, progressive autoimmune cholestatic liver disease characterised by immune-mediated destruction of small intrahepatic bile ducts. As bile acid accumulation drives hepatic inflammation and fibrosis, the disease can progress to cirrhosis and liver failure. It primarily affects women, and its rare disease classification reflects a global prevalence estimated at approximately 100,000 patients in the US. ALP remains the most widely used biochemical marker of cholestasis and disease activity, and its reduction — particularly below 1.67 times the upper limit of normal — is a regulatory-accepted surrogate for improved long-term outcomes.

Pemafibrate acts as a selective PPARα modulator, distinguishing it from non-selective fibrate-class drugs. By activating the nuclear receptor PPARα in hepatocytes, it regulates gene expression involved in lipid and bile acid metabolism. In the context of PBC, the proposed mechanisms include inhibition of bile acid synthesis, anti-inflammatory effects mediated through PPARα activation, and micellisation of hydrophobic bile acids — each of which could reduce hepatic bile acid load and attenuate cholestatic injury.

The AllSci BriefSystematic R&D and deal news. Daily.

The BTD was supported by preliminary data from trial K-808-2.01, with results presented at the European Association for the Study of the Liver (EASL) Congress in May 2026. Kowa’s announcement characterized these data as demonstrating a significant improvement over existing treatments as measured by ALP reduction, though specific numeric values, patient numbers, and p-values from K-808-2.01 were not disclosed in the company’s announcement.

Research context

The PBC second-line treatment landscape has become notably active. Ipsen’s elafibranor (Iqirvo), a dual PPARα/δ agonist, received US FDA accelerated approval in June 2024 and reported late-breaking Phase III data at EASL 2026 showing clinically meaningful ALP reductions and fatigue improvements, establishing it as the current PPAR-class benchmark in the indication. Seladelpar (Livdelzi), a selective PPARδ agonist developed by CymaBay Therapeutics and now marketed by Gilead Sciences, received full FDA approval in August 2024 following Phase III data demonstrating ALP response in 61.7% of treated patients versus 20.0% on placebo (p<0.001) in the RESPONSE trial. GSK's linerixibat (Lynavoy), an ileal bile acid transporter (IBAT) inhibitor, received FDA approval in March 2026 for the distinct indication of cholestatic pruritus in PBC.

Pemafibrate’s mechanistic profile as a selective PPARα modulator differs from elafibranor’s dual PPARα/δ activity and from seladelpar’s PPARδ selectivity. Kowa’s development strategy targets the same inadequate UDCA responder population addressed by both approved agents, meaning pemafibrate would enter a market with two established competitors if it reaches approval.


This article was generated with AI assistance and reviewed and edited by the AllSci editorial team Explore more at AllSci News: https://allsci.com/news/